Analgesics ROBERT G

Total Page:16

File Type:pdf, Size:1020Kb

Analgesics ROBERT G Postgrad Med J: first published as 10.1136/pgmj.60.710.876 on 1 December 1984. Downloaded from Postgraduate Medical Journal (December 1984) 60, 876-880 Analgesics ROBERT G. TWYCROSS M.A., D.M., F.R.C.P. Sir Michael Sobell House, The Churchill Hospital, Headington, Oxford Introduction different mechanisms. Such concepts are almost certainly an oversimplification. Aspirin and related There is no internationally agreed classification of drugs appear to act at several sites in relation to analgesics. The terms mild and strong are not always prostaglandin synthesis, some peripheral and some helpful. Codeine, for example, is usually classed with central (Ferreira, 1981). Morphine also acts both the former which obscures its pharmacological rela- centrally and peripherally, though the major anal- tionship with morphine and other narcotics. More- gesic effect is undoubtedly central. over, there are occasions when morphine (a 'strong analgesic') does not relieve pain which aspirin (a 'mild analgesic') does. Anti-pyretic and narcotic have Analgesics in perspective much in their favour, although nefopam does not fit There is always more to analgesia than analgesics.by copyright. into either category. The basic division into non- The importance of explaining in simple terms the narcotic (non-opioid) and narcotic (opioid) is impor- mechanism(s) underlying the patient's pain should tant. The advent of drugs that have morphine-like not be forgotten. Pain that does not make sense or, (agonist) properties when used alone but act as worse, is seen as a threat is always more intense than antagonists when given after or in association with pain which is understandable. morphine has complicated matters. As agonists and Many drugs affect pain. Some affect it indirectly, agonist-antagonists should not be prescribed concur- for example, antibiotics in cystitis or sinusitis and rently, the classification in Table 1 has much to penicillamine or gold in rheumatoid arthritis. These commend it. drugs act by modifying the pathological process, and It is generally considered that aspirin and non- fall outside the definition of analgesic. Spasmolytics, http://pmj.bmj.com/ steroidal anti-inflammatory drugs (NSAID) act peri- such as baclofen, diazepam (somatic muscle) and pherally and narcotics centrally, that is, within the probanthine (smooth muscle), are another group of central nervous system. Paracetamol (acetamino- pain-modulating drugs. phen) and nefopam also act centrally but via Surgery is a commonly employed measure for the management of acute severe pain (e.g. appendicec- TABLE 1. Classification of analgesics tomy), likewise, radiation therapy and cytotoxic chemotherapy in pain associated with cancer. The Narcotic agonist- use of such measures does not preclude the use of on September 29, 2021 by guest. Protected Narcotic agonists Non-narcotic antagonists analgesics. Best results are often obtained by adopt- Weak Aspirin Weak ing a 'broad spectrum' approach, using two or more Codeine Paracetamol Pentazocine treatments in combination. In some conditions, e.g. Dihydrocodeine Nefopam trigeminal neuralgia, a sequential approach may, Dextropropoxyphene Ethoheptazine however, be appropriate. Strong Strong The use ofanalgesics is best seen as simply one way Morphine Butorphanol of elevating a patient's pain threshold. Analgesics, Diamorphine Buprenorphine including narcotics, do not usually relieve pain caused Pethidine Nalbuphine by degenerative nerve damage (dysaesthetic and Levorphanol Phenazocine stabbing pains). The site ofthe neurological lesion and Methadone the type of pain determine which pharmacological measures are appropriate, if any (Table 2). Postgrad Med J: first published as 10.1136/pgmj.60.710.876 on 1 December 1984. Downloaded from Analgesics 877 Principles of use and forces the patient to be in pain for perhaps 3 out of every 6 hr. Persistent pain requires prophylactic (preventive) therapy TABLE 2. Neuromuscular classification of pain: implications for therapy Analgesics should be given regularly, and prophy- of pain Treatment lactically. The aim is to titrate the dose of the Type analgesic against the patient's pain, gradually in- (1) Muscle spasm Baclofen creasing the dose until the patient is pain-free. The Diazepam next dose is given before the effect of the previous (2) Nociceptive Analgesics one has fully worn off-and therefore before the (3) Nerve compression Analgesics patient may think it necessary (Fig. 1 and 2). In this Corticosteroids way it is possible to erase the memory and fear of Nerve blocks (4) Nerve destruction Psychotropic drugs pain. If a drug ceases to be effective, do not transfer (dysaesthetic) (especially antidepressants) to an alternative ofcomparable efficacy but prescribe peripheral nerve- Narcotics a drug that is definitely stronger. occasionally useful Corticosteroids If a strong analgesic other than morphine is used, cord lesion- Nerve blocks the physician must be familiar with its pharmacol- of no benefit Cordotomy (5) Mixed nerve Treated as mixed 3 and 4 ogy. For example, pethidine (meperidine) is effective compression and destruction (?)Stellate ganglion block for an average of 2-3 hr. Yet it is commonly (partly dysaesthetic) for upper limb pain prescribed every 4 or 6 hr. This is clearly insufficient, PAIN Toxicity by copyright. PD]p -] 1<\ \tl a t t 1 X E A Pain controlled Poor or no control 0 6 12 18 24 AS REQUIRED MEDICATION http://pmj.bmj.com/ FIG. 1. Diagram to illustrate the result of 'as required' morphine sulphate. [Dip= plasma concentration of drug. CONTINUOUS PAIN RELIEF Toxicity on September 29, 2021 by guest. Protected [L]p Pain controlled Poor or no control - 0 4 8 1-2 16 20 24 FOUR HOURLY DRUG REGIMEN FIG. 2. Diagram to illustrate the result of regular 4-hourly morphine sulphate. [D]p =plasma concentration of drug. Postgrad Med J: first published as 10.1136/pgmj.60.710.876 on 1 December 1984. Downloaded from 878 R. G. Twycross Use oral medication whenever possible (2) It may be appropriate to prescribe aspirin in addition to a narcotic, especially in patients with The route of administration is a significant con- bone pain. sideration because it has substantial impact on the It is to patient's way of life. The patient taking oral medica- (3) logical combine analgesics that act via tion is free to move around, travel in a car and, most different mechanisms, for example: aspirin and important, be at home. Injections promote depen- paracetamol; paracetamol and codeine; aspirin and dence on the person administering the Oral morphine. However, it is not always wise from the drug. point of view of patient compliance, nor is it always administration eliminates muscle trauma, and en- therapeutically necessary. ables the patient to maintain control over his own (4) It is pharmacological nonsense to prescribe either drug administration. two weak or two strong narcotics simultaneously. (5) There is sometimes a place for a patient on a Doses should be determined on an individual basis strong narcotic to have another narcotic (weak or The effective analgesic dose varies considerably strong) as a second as required analgesic for occa- from patient to patient. The right dose ofan analgesic sional troublesome pain, though generally patients is that which gives adequate relief for at least 3 and should be advised to take an extra dose of their preferably 4 or more hours. 'Maximum' or 'rec- regular medication if 'breakthrough' pain occurs. ommended' doses, derived mainly from post-opera- (6) If one weak narcotic preparation does not control tive parenteral single-dose studies, are not applicable the pain, do not waste time by prescribing an in cancer. The dose of morphine and other strong alternative; move to something definitely stronger. narcotic agonists can be increased almost indefin- (7) Morphine or an alternative strong narcotic should itely. On the other hand, the non-narcotics, weak be used when non-narcotics and weak narcotics fail narcotic agonists and narcotic agonist-antagonists all to control the pain (Table 3). reach a plateau of maximum effect after 2 or 3 (8) 'Morphine exists to be given, not merely to be upward dose adjustments. Thus, ifthe upper effective withheld.' The severity of the pain determines the dose has been reached with one of these agents, the choice of analgesic, not the doctor's estimate of lifeby copyright. dose should not be increased further but a stronger expectancy-which is often wrong. A patient should drug should be prescribed. not be made to wait in pain until the last days or hours of life. Keep it simple (9) Morphine may be given in a wide range of doses from as little as 5 mg to more than 500 mg. The three basic analgesics are aspirin, codeine and (10) Do not prescribe a narcotic agonist-antagonist, morphine. The rest should be considered alternatives such as pentazocine or buprenorphine, with a narco- of fashion or convenience. Appreciating this helps tic agonist. prevent 'kangarooing' from analgesic to analgesic in (11) Preferably do not prescribe pentazocine, pethi- a deperate search for some drug that will suit the dine or dextromoramide (Palfium). The first is a patient better. If a non-narcotic or weak narcotic weak narcotic by mouth and frequently causeshttp://pmj.bmj.com/ preparation, such as aspirin-codeine or paracetamol- unpleasant mental effects. All three tend to be short- dextropropoxyphene, fails to relieve, it is usually best acting (2-3 hr). to move directly to a small dose of oral morphine (12) Many cancer pains respond better to the sulphate than, for example, to prescribe dihydrocode- concurrent use of an analgesic and a 'co-analgesic' ine. (see Baines, 1984, this issue). It is necessary to be familiar with one or two alternatives for use in Adjuvant medication is often patients who cannot tolerate necessary on September 29, 2021 by guest. Protected the standard preparation. Aspirin has two alterna- Laxatives are almost always tives: paracetamol, which has no anti-inflammatory necessary, especially effect, is one: non-steroidal anti-inflammatory drugs with patients receiving a narcotic.
Recommended publications
  • SENATE BILL No. 52
    As Amended by Senate Committee Session of 2017 SENATE BILL No. 52 By Committee on Public Health and Welfare 1-20 1 AN ACT concerning the uniform controlled substances act; relating to 2 substances included in schedules I, II and V; amending K.S.A. 2016 3 Supp. 65-4105, 65-4107 and 65-4113 and repealing the existing 4 sections. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 Section 1. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as 8 follows: 65-4105. (a) The controlled substances listed in this section are 9 included in schedule I and the number set forth opposite each drug or 10 substance is the DEA controlled substances code which has been assigned 11 to it. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- 17 N-phenylacetamide)......................................................................9821 18 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- 19 piperidinyl]-N-phenylacetamide)..................................................9815 20 (3) Acetylmethadol.............................................................................9601 21 (4) AH-7921 (3.4-dichloro-N-[(1- 22 dimethylaminocyclohexylmethyl]benzamide)...............................9551 23 (4)(5) Allylprodine...........................................................................9602
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,541,026 B2 Qiu Et Al
    USOO8541026B2 (12) United States Patent (10) Patent No.: US 8,541,026 B2 Qiu et al. (45) Date of Patent: Sep. 24, 2013 (54) SUSTAINED RELEASE FORMULATIONS OF 4,612,008 A 9/1986 Wong et al. OPOD AND NONOPOD ANALGESCS 4,663,149 A 5, 1987 Eckenhoff et al. 4,681.583 A 7/1987 Urquhartet al. 4,717,569 A 1/1988 Harrison et al. (75) Inventors: Yihong Qiu, Vernon Hills, IL (US); 4,763,405 A 8, 1988 E" Cheri E. Klein, Northbrook, IL (US) 4,765,989 A 8/1988 Wong et al. 4,777,049 A 10/1988 Magruder et al. (73) Assignee: AbbVie Inc., North Chicago, IL (US) 4,783,337 A 1 1/1988 Wong et al. 4,786,503 A 11/1988 Edgren et al. (*) Notice: Subject to any disclaimer, the term of this 4,806.3594,801.461 A 2/19891/1989 RadebaughHamel et al. etal patent is extended or adjusted under 35 48 16,470 A 3, 1989 Dowle et al. U.S.C. 154(b) by 1219 days. 4,820,522 A 4, 1989 Radebaugh et al. 4,844,907 A 7/1989 Elger et al. (21) Appl. No.: 11/737,914 4,847,077 A 7, 1989 Raghunathan 4,892,778 A 1/1990 Theeuwes et al. 1-1. 4.915,949 A 4/1990 Wong et al. (22) Filed: Apr. 20, 2007 4.915,954. A 4/1990 Ayer et al. O O 4,931,285 A 6/1990 Edgren et al. (65) Prior Publication Data 4,940,465.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub
    US 2004.0024006A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub. Date: Feb. 5, 2004 (54) OPIOID PHARMACEUTICAL May 30, 1997, now abandoned, and which is a COMPOSITIONS continuation-in-part of application No. 08/643,775, filed on May 6, 1996, now abandoned. (76) Inventor: David Lew Simon, Mansfield Center, CT (US) Publication Classification Correspondence Address: (51) Int. Cl. ................................................ A61K 31/485 David L. Simon (52) U.S. Cl. .............................................................. 514/282 P.O. Box 618 100 Cemetery Road (57) ABSTRACT Mansfield Center, CT 06250 (US) The invention is directed in part to dosage forms comprising a combination of an analgesically effective amount of an (21) Appl. No.: 10/628,089 opioid agonist analgesic and a neutral receptor binding agent or a partial mu-opioid agonist, the neutral receptor binding (22) Filed: Jul. 25, 2003 agent or partial mu-opioid agonist being included in a ratio Related U.S. Application Data to the opioid agonist analgesic to provide a combination product which is analgesically effective when the combina (63) Continuation-in-part of application No. 10/306,657, tion is administered as prescribed, but which is leSS analge filed on Nov. 27, 2002, which is a continuation-in-part Sically effective or less rewarding when administered in of application No. 09/922,873, filed on Aug. 6, 2001, excess of prescription. Preferably, the combination product now Pat. No. 6,569,866, which is a continuation-in affects an opioid dependent individual differently from an part of application No. 09/152,834, filed on Sep.
    [Show full text]
  • Two Patterns of Narcotic Drug Addiction in the United States John C
    Journal of Criminal Law and Criminology Volume 56 Article 8 Issue 2 June Summer 1965 Two Patterns of Narcotic Drug Addiction in the United States John C. Ball Follow this and additional works at: https://scholarlycommons.law.northwestern.edu/jclc Part of the Criminal Law Commons, Criminology Commons, and the Criminology and Criminal Justice Commons Recommended Citation John C. Ball, Two Patterns of Narcotic Drug Addiction in the United States, 56 J. Crim. L. Criminology & Police Sci. 203 (1965) This Criminology is brought to you for free and open access by Northwestern University School of Law Scholarly Commons. It has been accepted for inclusion in Journal of Criminal Law and Criminology by an authorized editor of Northwestern University School of Law Scholarly Commons. RESEARCH REPORTS TWO PATTERNS OF NARCOTIC DRUG ADDICTION IN THE UNITED STATES JOHN C. BALL* Evidence from the present study and a review and has, in modern times, often reflected the tech- of the literature support the thesis that two quite nical and scientific advances in medicine and distinct patterns of narcotic drug addiction exist pharmacology with respect to the particular drug in the United States at the present time. One ad- taken and the means of administration employed diction pattern is followed by young heroin users by the user. Thus, the invention of the hypodermic who come predominantly from metropolitan cen- syringe facilitated both the medical and non- ters and are engaged in illegal endeavors. The other medical use of opiates in the United States after pattern is typified by the middle-aged southern 1856. The practice of opium smoking became white who uses morphine or paregoric and obtains somewhat of a vogue among the demi-monde of his drugs through legal or quasi-legal means.
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • Controlled Drug Schedules, Violations & Penalties
    CONTROLLED DRUG SCHEDULES, VIOLATIONS & PENALTIES A REFERENCE FOR THE LAW ENFORCEMENT COMMUNITY April 2015 Prepared by the DEPARTMENT OF CONSUMER PROTECTION Drug Control Division TABLE OF CONTENTS SECTION I CONTROLLED DRUG SCHEDULES & VIOLATIONS An alphabetical listing of controlled drugs by their brand, generic and/or street name that includes each drug’s schedule and the violation(s) from the Connecticut General Statutes (CGS) that are associated with each drug’s sale and/or possession. SECTION II CONTROLLED DRUG VIOLATIONS & PENALTIES A numerical listing of controlled drug violations by their section number in the Connecticut General Statutes (CGS) and the penalty(ies) associated with each violation. SECTION III SUMMARY OF FEDERAL METHAMPHETAMINE STATUTES 2 S E C T I O N I CONTROLLED DRUG SCHEDULES & VIOLATIONS The ‘Schedules of Controlled Substances’ may be found in Sections 21a-243-7 through 21a-243-11, inclusive, of the Regulations of Connecticut State Agencies. www.ct.gov/dcp/lib/dcp/dcp_regulations/21a-243_designation_of_controlled_drugs.pdf 3 Drug State CS Drug Type AKA Sale or Quantity Person Drug- CGS Schedule Possession? Dependent or Not Violation APAP = Acetaminophen APAP = Acetaminophen Drug-Dependent ? ASA = Aspirin ASA = Aspirin “2C-C” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-D” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-E” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-H” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-I” Designer Drug - Stimulant
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0129443 A1 Pettersson (43) Pub
    US 20100129443A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0129443 A1 Pettersson (43) Pub. Date: May 27, 2010 (54) NON-ABUSABLE PHARMACEUTICAL Publication Classification COMPOSITION COMPRISING OPODS (51) Int. Cl. A69/20 (2006.01) (76) Inventor: Anders Pettersson, Uppsala (SE) A6IR 9/14 (2006.01) Correspondence Address: 3. ?t C RYAN KROMHOLZ & MANION, S.C. (2006.01) POST OFFICE BOX 266.18 A6IP 25/00 (2006.01) MILWAUKEE, WI 53226 (US) (52) U.S. Cl. ......... 424/465; 424/489: 514/329; 514/282: 424/464 (21) Appl. No.: 12/312,995 (57) ABSTRACT (22) PCT Filed: Dec. 3, 2007 There is provided pharmaceutical compositions for the treat ment of pain comprising a pharmacologically-effective (86). PCT No.: PCT/GB2OOTFOO4627 amount of an opioid analgesic, or a pharmaceutically-accept S371 (c)(1) able salt thereof, presented in particulate form upon the sur (2), (4) Date: Jan. 12, 2010 faces of carrier particles comprising a pharmacologically s e -la?s effective amount of an opioid antagonist, or a O O pharmaceutically-acceptable Salt thereof, which carrier par Related U.S. Application Data ticles are larger in size than the particles of the opioid anal (60) Provisional application No. 60/872,496, filed on Dec. gesic. The compositions are also useful in prevention of 4, 2006. opioid abuse by addicts. US 2010/0129443 A1 May 27, 2010 NON-ABUSABLE PHARMACEUTICAL ing opioid analgesics, which may be administered by a con COMPOSITION COMPRISING OPODS Venient route, for example transmucosally, particularly, as is usually the case, when such active ingredients are incapable of being delivered perorally due to poor and/or variable bio 0001.
    [Show full text]
  • Outline for Controlled Substances Program
    Environmental Health and Safety Controlled Substances Program Date of Issuance: Review Date: 10/1/2019 (no changes) 10/01/2018 Revision Number: Initial Prepared by: EH&S Table of Contents HEADINGS Introduction Applicability Responsibilities Registration Requirements Authorized Use Ordering/Purchasing Administering and Dispensing Inventory Procedures (Continuing Records) Security Disposal FORMS: Registering or renewing a DEA or state license (CMU) Controlled Substances Authorized users list (CMU) Employee questionnaire for those with access to controlled substances (CMU) Record of Form 222 use (Order form) (CMU) Records of Controlled Substance Purchases (CMU) Record of Controlled Substance Administering and dispensing (CMU) Controlled Substance Physical Inventory (CMU) DEA Registration of Persons doing research or analysis (Form 225) DEA Registration of Dispensers (Form 224) DEA Registration Instructional (Form 224 and 226 to renew) DEA Report of loss or theft (Form 106) DEA Report of drugs surrendered (From 41) DEA SCHEDULES: Schedule I Schedule II Schedule III Schedule IV Schedule V INTRODUCTION State and Federal regulations have been promulgated concerning the use and handling of US Department of Justice Drug Enforcement Administration (DEA) controlled substances. These regulations are in place to address materials which are or have the potential to be addictive or habit forming. These substances have been categorized into “schedules” that have been created by the DEA to reflect their level of concern. The “Carnegie Mellon University DEA Controlled Substances Program” is intended to ensure that Carnegie Mellon University is in compliance with our regulatory requirements. Required activities under the DEA include: 1. Registration of your work with the DEA and with Carnegie Mellon’s Department of Environmental Health and Safety (EH&S).
    [Show full text]
  • (2) Patent Application Publication (10) Pub. No.: US 2017/0020885 A1 Hsu (43) Pub
    US 20170020885A1 (19) United States (2) Patent Application Publication (10) Pub. No.: US 2017/0020885 A1 Hsu (43) Pub. Date: Jan. 26, 2017 (54) COMPOSITION COMPRISING A (52) U.S. CI. THERAPEUTIC AGENT AND A CPC ......... A61K 31/5377 (2013.01); A61K 9/0053 RESPIRATORY STIMULANT AND (2013.01); A61K 31/485 (2013.01); A61 K METHODS FOR THE USE THEREOF 9/5073 (2013.01); A61K 9/5047 (2013.01): A61K 45/06 (2013.01); A61K 9/0019 (71) Applicant: John Hsu, Rowland Heights, CA (US) (2013.01); A61K 9/209 (2013.01) (72) Inventor: John Hsu, Rowland Heights, CA (US) (57) ABSTRACT (21) Appl. No.: 15/214,421 (22) Filed: Jul. 19, 2016 The present disclosure provides a safe method for anesthesia or the treatment of pain by safely administering an amount Related U.S. Application Data of active agent to a patient while reducing the incidence or severity of suppressed respiration. The present disclosure (60) Provisional application No. 62/195,769, filed on Jul. provides a pharmaceutical composition comprising a thera 22, 2015. peutic agent and a chemoreceptor respiratory stimulant. In one aspect, the compositions oppose effects of respiratory Publication Classification suppressants by combining a chemoreceptor respiratory (51) Int. Cl. stimulant with an opioid receptor agonist or other respira A6 IK 31/5377 (2006.01) tory-depressing drug. The combination of the two chemical A6 IK 9/24 (2006.01) agents, that is, the therapeutic agent and the respiratory A6 IK 9/50 (2006.01) stimulant, may be herein described as the “drugs.” The A6 IK 45/06 (2006.01) present compositions may be used to treat acute and chronic A6 IK 9/00 (2006.01) pain, sleep apnea, and other conditions, leaving only non A6 IK 31/485 (2006.01) lethal side effects.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]